Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$28.44 USD
+1.12 (4.10%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $28.36 -0.08 (-0.28%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Ultragenyx Pharmaceutical Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
RARE 28.44 +1.12(4.10%)
Will RARE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains?
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?
Other News for RARE
Tactical Resources Announces Execution Of Amendment To Business Combination Agreement With Plum Acquisition Corp. III
Ultragenyx (RARE) Completes Enrollment for Phase 3 Study on Angelman Syndrome Treatment
Ultragenyx Pharmaceutical Inc (RARE) Advances Phase 3 Aspire Study for Angelman Syndrome ...
Ultragenyx completes enrollment of GTX-102 trial
Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of ...